A Prospective, Open-label, Interventional Study to Assess the HbA1c Change an 24-hr Glucose Fluctuation After Vildagliptin Plus Metformain (SPC) Treatment in Metformin Monotherapy Uncontrolled Type 2 Diabetes Mellitus Patients
Phase of Trial: Phase IV
Latest Information Update: 05 Nov 2016
At a glance
- Drugs Vildagliptin/metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 10 Jun 2017 Biomarkers information updated
- 05 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 16 Apr 2014 Planned End Date changed from 1 Oct 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov.